Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib

Amgen is set to file for FDA approval of its KRAS G12C inhibitor sotorasib by the end of the year. The plan positions Amgen to become the first company to win approval for a drug against the historically undruggable KRAS.